Payment overview · 2025
General Payments
$94.35
5 reported records · 3 companies
Healthcare provider profile · identity verified
Chris Brussow, MD
Allopathic & Osteopathic Physicians|Family Medicine · PASCO, WA · NPI 1346726023
Verified facts
What the public records show
CMS Open Payments records show Chris Brussow, MD received $94.35 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 62.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.33 | 62.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.13 | 20.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.89 | 16.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.35 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 63 |
| Lisinopril | Lisinopril | 170 | 60 |
| Losartan Potassium | Losartan Potassium | 168 | 57 |
| Gabapentin | Gabapentin | 139 | 35 |
| Omeprazole | Omeprazole | 107 | 41 |
| Simvastatin | Simvastatin | 91 | 30 |
| Metformin Hcl | Metformin Hcl | 89 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 28 |
| Sertraline Hcl | Sertraline Hcl | 87 | 23 |
| Glipizide | Glipizide | 86 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 31 |
| Metformin Hcl Er | Metformin Hcl | 84 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 25 |
| Allopurinol | Allopurinol | 73 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 14 |
| Furosemide | Furosemide | 70 | 29 |
| Ozempic | Semaglutide | 69 | 14 |
| Trazodone Hcl | Trazodone Hcl | 69 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 20 |
| Jardiance | Empagliflozin | 67 | 19 |
| Tramadol Hcl | Tramadol Hcl | 67 | suppressed |
| Eliquis | Apixaban | 66 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 18 |
| Potassium Chloride | Potassium Chloride | 53 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Meloxicam | Meloxicam | 45 | 17 |
| Montelukast Sodium | Montelukast Sodium | 44 | 17 |
| Alendronate Sodium | Alendronate Sodium | 43 | 16 |
| Prednisone | Prednisone | 42 | 34 |
| Carvedilol | Carvedilol | 41 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 15 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Mirtazapine | Mirtazapine | 34 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 11 |
| Naproxen | Naproxen | 28 | 19 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.35 · 5 records | PFIZER INC. | COMIRNATY, ELIQUIS, MOUNJARO, NURTEC ODT, PENBRAYA, PREVNAR 20, TRUMENBA, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error